Kesimpta®
Aimovig® (Erenumab)
Aimovig ® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.Twitter Linkedin Facebook Pinterest Google plusTraining / Videos
Mechanism of Action
References: 1. Aimovig® Core Data Sheet v2.3. 2. Shi L, et al. J Pharmacol Exp Ther 2016; 356: 223-231. 3. Foltz IN, et al. Circulation 2013; 127(22): 2222-30. 4. Levin M, et al. Headache 2018; 58 (10): 1689-1696...
Twitter Linkedin Facebook Pinterest Google plusEfficacy
Safety Profile
A meta-analysis was performed based on scientific articles on databases of Genentech and Novartis and a systematic research of articles on PubMed, Medline, Web of Science & Embase with inclusion criteria:
Patients with CSU treated with...Twitter Linkedin Facebook Pinterest Google plusDosing / Administration
Figure 3: Dosing Xolair(r) – omalizumab1. Adapted from SmPC Xolair(r) (EMA, 2020)
The indicated dose for patients with chronic spontaneous urticaria is 300 mg (2 x 150 mg). It is administered by subcutaneous injection every 4...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action
Omalizumab is a humanized monoclonal antibody. The active substance will selectively bind to IgE causing a reduction in the binding of IgE to the FceRI receptor found on mast cells, among others. It is not entirely clear how this leads to an...
Twitter Linkedin Facebook Pinterest Google plusReimbursement